This study used small hairpin (sh)RNAmediated gene silencing to target VTCN1 (B7-H4) expression in a nonsmall-cell lung cancer (NSCLC) cell line (A549) and evaluated the effects on T cell immune activity using an in vitro coculture system.
Introduction
Lung cancer is highly prevalent and is the most common cause of cancer-related death worldwide. 1 The development of lung cancer is a complex process involving the accumulation of genetic mutations within tumour cells that confer the malignant phenotype, as well as alterations within the microenvironment to facilitate tumour progression. The immune response plays a critical role in detecting and eliminating cancerous cells in a process known as immunosurveillance, 2,3 with immunodeficiency often being associated with human cancer. 4 The ability of tumour cells to evade immunosurveillance is of such importance in cancer development that it is considered to be the seventh hallmark of cancer. 5 Mounting evidence suggests that two general strategies are utilized by tumour cells to escape immunosurveillance: immunoselection (poorly immunogenic tumour cell S-Q Sun, C-G Jiang, Y Lin et al. B7-H4 in NSCLC T cell immunity variants) and immunosubversion (subversion of the immune system). 6 In spite of intensive research, effective new immunotherapies for slowing tumour progression and preventing its recurrence are lacking. 7 It is, therefore, essential to gain further understanding of the molecular mechanisms of immuno selection and immunosubversion.
The molecule B7-H4, also known as B7x, B7S1 or VTCN1, is a member of the B7 family of immune regulatory molecules. B7-H4 has profound inhibitory effects on T cell immunity including cell growth, cytokine production and cytotoxic activity. 8 -10 In humans, B7-H4 is encoded by VTCN1, which spans a 66.6 kb region of chromosome 1p11.1, and contains six exons and five introns. 11 Alternative splicing within exon 6 generates two different transcripts of approximately 2000 and 800 base pairs with identical open reading frames. B7-H4 protein is not detectable in most tissues from healthy individuals but, in vitro, it is inducible in human immune cells such as T cells, B cells, monocytes and dendritic cells. 8 Studies have reported the upregulation of B7-H4 in a variety of cancers including ovarian, breast and lung cancer. 12 -15 In nonsmall-cell lung cancer (NSCLC), 43% of tumour tissues were found to be positive for B7-H4 expression, and increased B7-H4 levels were associated with a decline in T infiltrating lymphoid cell numbers, and an increase in lymph node metastasis and B7-H3 levels. 14 We, therefore, thought that upregulation of B7-H4 may be a mechanism by which tumour cells suppress T cell immunity and facilitate tumour progression.
The aim of the current study was to test this hypothesis via knockdown of endogenous VTCN1 expression, using small hairpin (sh)RNA-mediated gene silencing in the human NSCLC cell line, A549. The effects of this knockdown on T cell immune activities were examined using an in vitro coculture system with Jurkat cells (an immortalized T cell leukaemia cell line maintaining functional characteristics of activated T cells), as a model for T lymphocytes. 16, 17 
Materials and methods

CONSTRUCTION OF SHRNA-CONTAINING PLASMID
The shRNA sequence targeting the human VTCN1 gene (Gene ID: 79679) was designed following small interfering (si)RNA design guidelines (http://www.ambion.com) and was purchased from Shanghai GeneChem (Shanghai, China). The sequence was: sense 5′gaGTCACCTACAGCTGCTAAAttcaagagaTT TAGCAGCTGTAGGTGACtc3′, where the lower case letters 'ttcaagaga' indicate the loop sequence for the short hairpin structure. The synthesized duplex shRNA sequence was cloned into BamHI/HindIII-digested pGCsi-U6/GFP plasmid (Shanghai GeneChem) to generate pGCsi-U6/GFP/VTCN1. The inserted sequence was confirmed by sequencing.
CELL LINES
The human lung adenocarcinoma cell lines A549, SPCA1 and GLC82 were obtained from the Central Laboratory (School of Medicine, Southeast University, Nanjing China) and the immortalized T lymphocyte Jurkat cell line was obtained from the Shanghai Institutes for Biological Science (Shanghai, China). All cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sijiqing Company, Hangzhou, China), 100 kU/l penicillin and 100 kU/l streptomycin (Gibco) at 37°C with 5% carbon dioxide. The steady state level of VTCN1 mRNA in each cell line was assessed via semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), as described below.
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TRANSFECTION OF A549 CELLS
The A549 cells were plated at 1 × 10 5 cells/well in six-well plates and cultured to 90% confluency. Cells were then transfected with pGCsi-U6/GFP/VTCN1 or empty pGCsi-U6/GFP vector using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions, to generate A549/shVTCN1 or A549/Vec cells, respectively. Mock-transfected (A549/Mock) cells were used as controls. The antibiotic G418 (final concentration 600 µg/ml) was added to A549/Vec and A549/shVTCN1 cells 24 h after transfection. Antibiotic selection proceeded for 14 days with the medium changed every 2 days. The resulting stably transfected A549/Vec and A549/shVTCN1 cells were used for further experiments.
COCULTURE OF A549 AND JURKAT CELLS
The A549/shVTCN1, A549/Vec or A549/Mock cells were harvested and seeded into 25 cm 2 tissue culture flasks at 2 × 10 5 cells/ml, in a total volume of 10 ml/flask. When cells reached 80% confluency, the old medium was removed and 10 ml of fresh medium containing 3 × 10 5 cells/ml Jurkat T cells was added. After 24 h, the flask was gently shaken to dislodge loosely attached Jurkat cells and the culture medium was transferred to a 10 ml centrifuge tube. Ethylene diaminetetra-acetic acid (EDTA)-free trypsin (Ameresco, Framingham, MA, USA) was added to the flask and incubated with the attached cells for 24 h until the majority of Jurkat cells were lifted, but A549 cells remained attached. The lifted Jurkat cells were pooled with those from the cultured medium and centrifuged at 200 g for 5 min, at 37°C, for further analysis.
SEMIQUANTITATIVE RT-PCR
Interferon (IFN)-γ, interleukin (IL)-10, IL-2, VTCN1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression was detected by semiquantitative RT-PCR. Total RNA was extracted from 1 × 10 7 Jurkat cells using TRIzol ® reagent (Invitrogen, Groningen, The Netherlands), and 3 µg was used for RT using an RT kit (Takara Bio, Shiga, Japan). The resulting cDNA was used as a template for PCR, using an RNA LA PCR Kit (AMV) (Takara Bio) and a Mastercycler ® Gradient Thermal Cycler (Eppendorf, Hamburg, Germany).
The sequences, annealing temperatures and amplicon sizes for the primers used are given in Table 1 . All primers were synthesized by Takara Bio. The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at the appropriate temperature for 30 s and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 7 min. The PCR products were separated by electrophoresis in a 2% agarose gel, and visualized with ethidium bromide and ultraviolet light. Densitometric analysis was performed using Scion Image software (Scion Corp., Frederick, MD, USA) and the inhibition level of VTCN1 mRNA was calculated as follows: inhibition level = (1 -(VTCN1 density/GAPDH density) A549/shVTCN1 or A549/Vec /(VTCN1 density/GAPDH density) A549/Mock ) × 100%.
WESTERN BLOTTING
The A549/Vec and A549/shVTCN1 cells (1 × 10 5 ) were harvested and lysed in 60 µl cell lysis solution containing 20 mM Tris (pH 7.5), 150 mM sodium chloride, 5 mM sodium pyrophosphate, 2 mM β-glycerophosphate, 5 mM EDTA, 2 mM sodium orthovanadate and 1 µg/ml leupeptin (Beyotime Biotech, Shanghai, China). Total protein concentration was determined with a Bio-S-Q Sun, C-G Jiang, Y Lin et al. 
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CELL PROLIFERATION (MTT) ASSAY
Jurkat cells collected from coculture with A549 cells were seeded into 96-well plates at 2 × 10 4 cells/well (time 0). At 0, 24, 48 and 72 h after seeding 20 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) stock solution (5 mg/ml) was added to each well and incubated at 37°C for 4 h. The supernatant was then carefully removed, 150 µl dimethylsulphoxide was added to each well and the 96-well plate was gently shaken for 10 min to dissolve the formazan crystals. The optical density (OD) of the dissolved solution was read at 492 nm on a microreader (Bio-Rad Laboratories). Subsamples from each treatment group were 
ANALYSIS OF APOPTOSIS AND CELL CYCLE DISTRIBUTION
Jurkat cells cocultured for 72 h with A549/Mock, A549/Vec or A549/shVTCN1 cells were suspended in 0.01 M phosphatebuffered saline (PBS; pH 7.2) at 1 × 10 5 cells/ml, fixed with cold 70% ethanol in PBS at 4°C overnight, washed twice with PBS and centrifuged at 800 g for 5 min. Cells were incubated with 100 U/ml RNase A (Sigma) at 37°C for 30 min, then stained with 1 µg/ml propidium iodide in PBS for 10 -15 min at room temperature and analysed with a flow cytometer (FACSCalibur™, BD Biosciences, San Jose, CA, USA). 18 
STATISTICAL ANALYSES
Data were presented as mean ± SD for three independent experiments. One-way analysis of variance was used to evaluate differences between multiple groups and the Tukey-Kramer least significant difference post hoc test was employed in pairwise comparisons between two groups. Statistical evaluation of the data was carried out using SPSS ® version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered to be statistically significant.
Results
The results of screening three human lung adenocarcinoma cell lines, SPCA1, GLC82 and A549 for steady-state VTCN1 mRNA levels are shown in Fig. 1A . All three cell lines expressed similar high levels of VTCN1 mRNA.
Transfection with pGCsi-U6/GFP/VTCN1 significantly reduced levels of VTCN1 mRNA (Fig. 1B) and B7-H4 protein (Fig. 1C) compared with control cells (A549/Mock and A549/Vec) (P < 0.05). The levels of VTCN1 mRNA and B7-H4 protein did not differ significantly between A549/Mock and A549/Vec cells. 
α-Tubulin
Vec sh VTCN1 A549 B7-H4 in NSCLC T cell immunity Both A549/Mock and A549/Vec cells dramatically inhibited the growth of Jurkat cells over a 72-h period (Fig. 2) . In contrast, A549/shVTCN1 cells caused minimal growth inhibition of Jurkat cells (Fig. 2, P < 0.05) .
Jurkat cells cocultured with either A549/Mock or A549/Vec exhibited a detectable level of apoptosis (5.36% ± 0.45% and 6.14% ± 0.36%, respectively, difference not significant; Fig. 3A, 3B) , whereas those co-cultured with A549/shVTCN1 cells showed significantly reduced apoptosis (0.27% ± 0.07%; P < 0.05; Fig. 3C ). Jurkat cells cocultured with A549/shVTCN1 also exhibited a significantly reduced percentage of cells in the G 1 phase and a higher percentage in the S + G 2 /M phase, compared with those cocultured with A549/Mock or A549/Vec (P < 0.05; Fig. 3D) .
The mRNA and protein levels of IFN-γ, IL-10 and IL-2 were upregulated in Jurkat cells cocultured with A549/shVTCN1 compared with those cocultured with A549/Mock or A549/Vec (Fig. 4 ).
Discussion
The T lymphocytes, with their multiple types and secreted cytokines, play active roles in cancer immunoediting. CD8 + cytotoxic T lymphocytes (CTLs) recognize and kill cancer cells in a major histocompatibility complex (MHC) class I-dependent manner, and CD4 + T helper (Th) cells regulate macrophage polarization in a MHC class II-dependent * B7-H4 in NSCLC T cell immunity manner. 6 Th1 cells have been shown to activate antitumour M1 macrophages, while Th2 cells favour the protumour M2 macrophages. 6 CD8 + CTLs and Th1 cells are characterized by the production of IFN-γ (an antitumour and antiangiogenic cytokine 19 ), and Th2 cells produce the tumour-and metastasis-promoting IL-4. 20 These cells form a complex regulatory network within the tumour microenvironment. 21 The Th cells are activated from naïve T cells by T cell receptor-recognizing antigen-presenting cells (APCs) or MHC class II-expressing tumours, via costimulatory molecules including the B7 and tumour necrosis factor families of receptors. 22, 23 Upon initial activation, these molecules mediate coinhibitory signalling to fine-tune the activation of the T cell response. The B7 signalling pathway promotes T cell activation and differentiation via the engagement of T cellbased CD28 with B7-1 and B7-2 (CD80 and CD86, respectively) located on APCs. 24, 25 In contrast, B7 molecules evoke an inhibitory signal when engaged to the CTL associated gene-4 (CTLA-4) receptor on activated T cells. 26 The present study focused on B7-H4 (VTCN1), which is a member of the B7 family and has inhibitory effects on the T cell mRNA is present at high concentrations in a number of human lung cancer cell lines. It has been previously reported that 43% of NSCLC tumour tissues were positive for B7-H4, but A549 was the only NSCLC cell line to express B7-H4 (among A549, H1299, H23, Wark, U1810 and U1752). 14 The present study, therefore, selected A549 cells to test the role of B7-H4 in the crosstalk between tumour cells and T lymphocytes. Following stable knockdown of VTCN1 in A549 cells in the present study, the reduced B7-H4 level in tumour cells rescued growth inhibition, inhibited apoptosis, released G 1 cell cycle arrest and stimulated the production of IFNγ, IL-2 and IL-10 in an immortalized T cell leukaemia cell line.
Although no cognate receptor for B7-H4 has been identified to date, the functions of B7-H4 signalling in T cell responses have been well characterized. In anti-CD3 antibody-activated T cells, immobilized B7-H4 immunoglobulin inhibits proliferation of CD4 + and CD8 + T cells, production of cytokines and generation of alloreactive CTLs. 8 -10,27 It has been consistently reported that blocking B7-H4 with monoclonal antibody exacerbates experimental autoimmune encephalo myelitis in vivo. 8, 9 In B7-H4-knockout BALB/c mice, Th1 responses were only mildly augmented compared with wild-type mice and CTL reactions to viral infection were normal, 28 implying a minimal impact of B7-H4 deficiency. This suggests the presence of other negative cosignalling molecules that may work together with B7-H4 to fine-tune the T cell mediated immune response. 28 Knockdown of B7-H4 stimulated the production of IFN-γ, IL-2 and IL-10 in cocultured T lymphocytes in the present B7-H4 in NSCLC T cell immunity study, indicating an inhibitory effect of B7-H4 on the production of these cytokines. B7-H4 has been shown to inhibit the secretion of IFN-γ, IL-2, IL-4 and IL-10 from T cells costimulated with B7-1. 8 In contrast, B7-H4 antibody has been shown to stimulate the proliferation and secretion of IL-2 from T lymphocytes. 29, 30 The intracellular transcription factor JunB was shown to be downregulated by approximately 50% under costimulation by B7-H4 immunoglobulin. 9 Since JunB is a positive regulator for IL-2, B7-H4 may negatively regulate IL-2 production. Regulatory T cells were shown to stimulate the production of IL-10 from APCs and the subsequent upregulation of B7-H4, thereby initiating a negative feedback loop. 31 Several groups have reported inhibitory activities of B7-H4 on T cell responses, mainly using purified B7-H4 protein. 8 -10 The design of the current study has several advantages over these previous studies. First, by establishing an in vitro coculture system, this study better mimicked the clinical situation in which tumour cells (the source of B7-H4) are in direct contact with T lymphocytes. Secondly, the in vitro coculture system provides a highly reproducible platform to characterize further the molecular signalling pathways within both cell types. Thirdly, the loss-of-function approach used to knockdown endogenous VTCN1 expression provided information about the essential roles of B7-H4 in T cell immune activities, in contrast to the sufficiency studies performed with purified B7-H4. The design of the present study did not, however, allow for investigation of the in vivo functions of B7-H4 in tumour immunosurveillance; this topic will be addressed in future studies.
Costimulatory molecules are promising targets for therapeutic intervention in T cellregulated or mediated immune disorders, due to their pivotal role in T cell regulation. The present study supports the notion that the suppressive functions of coinhibitory molecules, such as B7-H4, may become a powerful tool for activating T cell responses in vivo and for enhancing antitumour immunity. 32 
